# Guillain-Barré Syndrome

Guillain-Barré syndrome is an acute immune-mediated polyradiculoneuropathy requiring prompt recognition of progressive weakness, areflexia, cranial or autonomic involvement, and respiratory risk. Diagnosis is clinical, supported by cerebrospinal fluid and electrodiagnostic testing; IVIG or plasma exchange plus intensive supportive care are established treatments.

**Clinical question:** How should physicians recognize, confirm, monitor, and treat suspected Guillain-Barré syndrome?

Updated: 2026-08-21T00:34:47.502784+00:00

## What matters in practice
- Suspect GBS with rapidly progressive, usually symmetric motor weakness and reduced or absent reflexes, often with paresthesias, cranial neuropathies, pain, or autonomic dysfunction. [5][12]
- CSF albuminocytologic dissociation and electrophysiologic abnormalities support GBS but should complement—not delay—a clinical diagnosis and urgent monitoring. [5][8][21]
- IVIG and plasma exchange are proven, equally effective immunotherapies; supportive management must anticipate respiratory failure, dysautonomia, immobility complications, and rehabilitation needs. [15][16][18]
- Progression to nadir beyond 4 weeks should prompt reconsideration of the diagnosis, including acute-onset CIDP. [13]

## Recognize GBS and identify patients needing monitored care

GBS is a clinical emergency because neuromuscular and autonomic deterioration can evolve rapidly.

GBS is an acute immune-mediated peripheral neuropathy with heterogeneous demyelinating and axonal forms. The classic syndrome includes progressive motor difficulty, absent deep-tendon reflexes, paresthesias without objective sensory loss, and CSF albuminocytologic dissociation. [5] An antecedent respiratory or gastrointestinal illness occurs in approximately two thirds of patients and may precede neurologic symptoms by up to 6 weeks. [12]

Assess trajectory, bulbar function, facial weakness, cough effectiveness, respiratory symptoms, autonomic symptoms, pain, and ability to walk independently at presentation and serially. Severe generalized GBS with respiratory failure affects approximately 20% to 30% of cases; one source estimates that one quarter of patients require assisted ventilation. [15][12] Cranial nerve and autonomic involvement are common in severe disease and should lower the threshold for monitored or intensive care. [11][12]
- Escalate urgently for rapidly progressive weakness, dysphagia, facial or other cranial neuropathies, respiratory compromise, or suspected autonomic instability. [12][15]
- Monitor pulse and blood pressure closely when autonomic dysfunction is a concern; substantial autonomic instability is a recognized complication of acute flaccid neuropathies. [19]
- Do not assume all acute flaccid paralysis is GBS: botulism, myasthenia gravis, Lambert-Eaton syndrome, tick paralysis, stroke, meningitis/encephalitis, and other neurologic disorders may mimic it. [19]

*Clinical findings that support GBS or require diagnostic reconsideration. [5][12][13][19]*

| Finding | Interpretation and next action |
| --- | --- |
| Rapidly progressive weakness with hyporeflexia or areflexia | Strongly supports GBS in the appropriate clinical course; arrange urgent neurologic assessment and serial respiratory/autonomic evaluation. [5][12] |
| Paresthesias with little objective sensory loss | Typical supportive phenotype; does not exclude important pain or sensory symptoms. [5] |
| Cranial neuropathy, dysphagia, or facial weakness | Supports a GBS-spectrum presentation and increases airway/aspiration concern. [11][21] |
| Weakness progressing beyond 4 weeks | Reconsider GBS; acute-onset CIDP and other mimics become more likely. [13] |
| Prominent descending paralysis, pupillary/autonomic features, or exposure-compatible illness | Evaluate urgently for botulism and contact public-health resources when suspected. [19] |

## Use CSF and electrodiagnostics to support a clinical diagnosis

Testing confirms phenotype, excludes mimics, and can be initially nondiagnostic early in disease.

GBS remains clinically defined. CSF albuminocytologic dissociation—elevated protein with a normal cell count—is a classic supportive finding. [5] In a Puerto Rico surveillance cohort, GBS diagnostic confirmation used standardized Brighton Collaboration criteria incorporating clinical presentation, CSF findings, and electrophysiology. [21]

Order nerve-conduction studies and electromyography to support GBS and characterize demyelinating versus axonal physiology. Early studies may be incomplete or nonspecific: absent H reflexes were reported as the most sensitive early electrodiagnostic finding, while upper-extremity sensory nerve action potentials, F waves, and other parameters may also be abnormal. [8] A nondiagnostic early study should not override a convincing evolving clinical syndrome or delay disposition and supportive management. [8][15]
- Use CSF and electrodiagnostic results as supportive evidence in the context of the clinical course rather than as standalone rule-in tests. [5][21]
- Use electrodiagnostic classification to distinguish demyelinating and axonal forms, recognizing that GBS is clinically and pathologically heterogeneous. [5][12]
- Pursue targeted alternative testing when the phenotype is atypical, particularly for botulism, myasthenia gravis, Lambert-Eaton syndrome, central nervous system disease, or acute flaccid myelitis. [19][20]

*Diagnostic studies in suspected GBS. [5][8][21]*

| Study | High-value interpretation |
| --- | --- |
| Lumbar puncture | Elevated CSF protein with a normal cell count supports albuminocytologic dissociation. [5][21] |
| Nerve-conduction studies/EMG | Supports peripheral neuropathy and helps classify demyelinating versus axonal disease; early testing may show absent H reflexes and other abnormalities. [8] |
| Clinical trajectory | Acute progression with nadir by 4 weeks is compatible with GBS; longer progression should prompt reassessment for CIDP or another diagnosis. [13] |

## Treat with IVIG or plasma exchange and deliver anticipatory supportive care

Immunotherapy does not replace vigilant respiratory, autonomic, thromboembolic, pain, nutritional, and rehabilitation management.

IVIG and plasma exchange are the two proven immunotherapies for GBS and are described as equally effective. [16][18] A major review likewise identifies either IVIG or plasma exchange, alongside supportive care, as optimal management. [15] The supplied sources do not provide treatment-selection criteria, U.S. dosing regimens, timing windows, contraindications, or evidence supporting combination or repeat therapy; clinicians should verify these details in current specialty guidance and local protocols.

Supportive care is central because respiratory failure, cranial neuropathy with dysphagia, autonomic dysfunction, pain, and prolonged disability drive acute morbidity. [11][12][15] Patients with clinically significant disability require coordinated rehabilitation; pediatric consensus guidance identifies combined rehabilitation procedures as necessary for patients with significant disability. [11]
- Admit and monitor patients with meaningful progression or bulbar, respiratory, or autonomic involvement; ICU-level care may be required. [12][15][21]
- Choose IVIG or plasma exchange as disease-directed therapy; both are established options. [16][18]
- Assess and manage neuropathic pain, swallowing safety, nutritional needs, mobility, skin integrity, and rehabilitation requirements throughout the acute course. Pain occurs in up to 70% of pediatric patients in one guideline and can be severe. [11]
- Avoid extrapolating treatment approaches for acute flaccid myelitis to GBS; CDC specifically states that AFM guidance is not intended for GBS or other immune-mediated acute flaccid paralysis etiologies. [20]

*Management priorities in acute GBS. [11][15][16][18]*

| Priority | Clinical action |
| --- | --- |
| Immunotherapy | Use IVIG or plasma exchange; available evidence describes them as proven and equally effective. [16][18] |
| Respiratory and airway safety | Perform serial clinical assessment for respiratory compromise and bulbar dysfunction; respiratory failure occurs in approximately 20% to 30% of severe generalized cases. [15] |
| Autonomic surveillance | Closely follow pulse and blood pressure when dysautonomia is suspected. [19] |
| Rehabilitation | Initiate coordinated rehabilitation planning for significant disability. [11] |

## Counsel on variable recovery and reassess an atypical course

GBS is often monophasic, but residual disability and diagnostic evolution require follow-up.

GBS is generally monophasic and typically reaches its nadir by 4 weeks. [13] Recovery is variable: CDC notes that most affected people recover fully, although some have long-term nerve damage and some deaths occur, usually from respiratory difficulty. [22] Axonal and demyelinating forms may have different recovery patterns, reinforcing the value of electrodiagnostic characterization and functional follow-up. [5][8]

At follow-up, document walking ability, cranial and respiratory recovery, pain, fatigue, sensory symptoms, autonomic symptoms, and return to activities. Persistent progression or recurrent deterioration should trigger diagnostic reassessment, including acute-onset CIDP, rather than automatic escalation of GBS treatment. [13]
- In the United States, GBS occurs in approximately 1 to 2 per 100,000 persons annually and incidence increases with age, with greatest risk reported in adults older than 50 years. [22]
- Seasonal influenza vaccination has, when detected, been associated with only a small excess risk of approximately 1 to 2 additional GBS cases per million doses; most GBS cases are not vaccine-associated. [22]

*Follow-up signals requiring reassessment. [13][22]*

| Clinical course | Implication |
| --- | --- |
| Improving monophasic illness after acute nadir | Consistent with typical GBS recovery; continue rehabilitation and assess residual deficits. [13][22] |
| Progression continuing beyond 4 weeks | Reconsider diagnosis, particularly acute-onset CIDP. [13] |
| Persistent weakness, sensory deficits, fatigue, pain, or loss of independence | Assess function and rehabilitation needs; long-term nerve damage can occur. [22] |

## Interpret vaccine-associated risk in clinical context

Vaccination-associated GBS concerns should be framed against the rarity of the event and infection-related triggers.

Most GBS cases are not associated with vaccines. [22] CDC reports that evidence regarding seasonal influenza vaccine and GBS varies across seasons; if increased risk exists, it is small—about 1 to 2 additional cases per million vaccine doses administered. [22] This information supports balanced counseling rather than attributing GBS to vaccination without an appropriate temporal and clinical assessment.
- Ask about antecedent respiratory and gastrointestinal illnesses occurring within the preceding 6 weeks. [12]
- Document recent vaccination as part of the exposure history, but recognize that temporal association alone does not establish causation. [22]

*Exposure history relevant to suspected GBS. [12][22]*

| Exposure | Clinical relevance |
| --- | --- |
| Respiratory or gastrointestinal illness within 6 weeks | Reported in approximately two thirds of patients and supports a postinfectious context. [12] |
| Seasonal influenza vaccination | Any increased risk is small, estimated by CDC at 1 to 2 additional cases per million doses when present. [22] |

## Common questions

### Can normal early electrodiagnostic testing exclude Guillain-Barré syndrome?

No. Early electrodiagnostic findings can be limited; absent H reflexes may be the most sensitive early abnormality. Interpret testing with the clinical course and repeat or reassess when suspicion remains high. [8]

### Are IVIG and plasma exchange both effective for Guillain-Barré syndrome?

Yes. Available reviews describe IVIG and plasma exchange as proven and equally effective treatments for GBS. [16][18]

### When should acute-onset CIDP be considered instead of GBS?

Consider acute-onset CIDP or another diagnosis when progressive weakness continues beyond 4 weeks, because GBS typically reaches nadir by that time. [13]

### How large is the reported influenza vaccine-associated GBS risk?

CDC reports that if an increased risk occurs after seasonal influenza vaccination, it is small, on the order of 1 to 2 additional GBS cases per million doses; most GBS cases are not vaccine-associated. [22]

## References
1. This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021266s049,021267s059,021630s038lbl.pdf
2. 3722330 This label may not be the latest approved by FDA ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021976s039,202895s016lbl.pdf
3. 3607428 This label may not be the latest approved by FDA ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020156s051lbl.pdf
4. 4075370 This label may not be the latest approved by FDA ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020636s048,020933s038lbl.pdf
5. Guillain-Barre syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/176
6. Anxiety and depression and their impact on functional ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/16/8/e111943
7. What Is Guillain-Barré Syndrome? | Neurology — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2801220
8. Early Electrodiagnostic Findings in Guillain-Barré Syndrome — jamanetwork.com — https://jamanetwork.com/journals/jamaneurology/fullarticle/779622
9. Guillain-Barré syndrome following COVID-19 — casereports.bmj.com — https://casereports.bmj.com/content/13/6/e236182
10. Neutrophil-to-lymphocyte ratio is a risk indicator of Guillain ... — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(23)01528-1
11. Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1090379820300040
12. Guillain-Barré Syndrome - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/immunology-and-microbiology/guillain-barre-syndrome
13. Autoimmune neuropathies: New guidelines and expert insights into clinical decision making — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0022510X25022798
14. Guillain‐Barré syndrome: a comprehensive review - Bellanti — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/ene.16365
15. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS) — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0755498213005058
16. Intravenous immunoglobulin and plasma exchange ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/mus.28265
17. European Academy of Neurology/Peripheral Nerve Society ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/jns.12594
18. Management of Guillain–Barré syndrome in Bangladesh ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jns.12597
19. Clinical Guidelines for Diagnosis and Treatment of ... — www.cdc.gov — https://www.cdc.gov/mmwr/volumes/70/rr/rr7002a1.htm
20. Clinical Guidance for the Acute Medical Treatment of AFM | Acute Flaccid Myelitis (AFM) | CDC — www.cdc.gov — https://www.cdc.gov/acute-flaccid-myelitis/hcp/clinical-guidance/index.html
21. Guillain-Barré Syndrome During Ongoing Zika Virus Transmission — Puerto Rico, January 1–July 31, 2016  | MMWR — www.cdc.gov — https://www.cdc.gov/mmwr/volumes/65/wr/mm6534e1.htm
22. Guillain-Barré Syndrome and Flu Vaccine | Influenza (Flu) | CDC — www.cdc.gov — https://www.cdc.gov/flu/vaccine-safety/guillainbarre.html
23. Management of irAEs Guideline (Part 9) | Podcast — ascopubs.org — https://ascopubs.org/do/nervous-system-toxicities-management-iraes-guideline-part-9
24. Guillain-Barré Syndrome and Visual Impairment Associated with Emerging Oropouche Virus Lineage, Brazil, 2024 - Volume 32, Number 4—April 2026 - Emerging Infectious Diseases journal - CDC — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/32/4/25-0617_article

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.